Development of Tracheoesophageal Fistula after the Use of Sorafenib in Locally Advanced Papillary Thyroid Carcinoma: a Case Report.
10.11106/ijt.2016.9.2.210
- Author:
Eyun SONG
1
;
Kyung Mee SONG
;
Won Gu KIM
;
Chang Min CHOI
Author Information
1. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. wongukim@amc.seoul.kr
- Publication Type:Case Report
- Keywords:
Tracheoesophageal fistula;
Sorafenib;
Thyroid cancer;
Papillary
- MeSH:
Fistula;
Follow-Up Studies;
Humans;
Iodine;
Jejunostomy;
Mortality;
Nutritional Support;
Thyroid Gland*;
Thyroid Neoplasms*;
Tracheoesophageal Fistula*
- From:International Journal of Thyroidology
2016;9(2):210-214
- CountryRepublic of Korea
- Language:English
-
Abstract:
Sorafenib, an oral multi-kinase inhibitor, is used for the treatment of patients with radioactive iodine (RAI) refractory differentiated thyroid carcinoma (DTC) with favorable outcomes. Some unusual but fatal adverse effects are known for this drug and tracheoesophageal fistula (TEF) is one of them, which has never been reported in thyroid cancer patients. We present a successfully treated patient who had developed TEF associated with rapid tumor regression during sorafenib treatment for locally advanced papillary thyroid carcinoma (PTC). Sorafenib was discontinued and feeding jejunostomy tube was placed for nutritional support. 3 months later, the TEF had successfully healed and there was no visible fistula track or interval change of the viable tumor during 15 months of follow-up. Identifying patients at high risk for this potential complication and paying special attention when prescribing anti-angiogenics to these patients are crucial to prevent associated morbidity and mortality.
